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Although hepatocellular carcinoma (HCC) has become a recognized indication for liver transplantation, the rules governing
priority and access to the waiting list are not well deﬁned. Patient- and tumor-related variables were evaluated in 226 patients
listed primarily for HCC in Belgium, a region where the allocation system is patient-driven, priority being given to sicker patients,
based on the Child-Turcotte-Pugh (CTP) score. Intention-to-treat and posttransplantation survival rates at 4 years were 56.5
and 66%, respectively, and overall HCC recurrence rate was 10%. The most signiﬁcant predictors of failure to receive a
transplant in due time were baseline CTP score equal to or above 9 (relative risk [RR] 4.1; conﬁdence interval [CI]: 1.7-9.9) and
 fetoprotein above 100 ng/mL (RR 3.0; CI: 1.2-7.1). Independent predictors of posttransplantation mortality were age equal
to or above 50 years (RR 2.5; CI: 1.0-3.7) and United Network for Organ Sharing pathological tumor nodule metastasis above
the Milan criteria (RR 2.1; CI: 1.0-5.9). Predictors of recurrence (10%) were  fetoprotein above 100 ng/mL (RR 3.2; CI:1.1-10)
and vascular involvement of the tumor on the explant (RR 3.6; CI: 1.1-11.3). Assessing the value of the pretransplantation
staging by imaging compared to explant pathology revealed 34% accuracy, absence of carcinoma in 8.3%, overstaging in
36.2%, and understaging in 10.4%. Allocation rules for HCC should consider not only tumor characteristics but also the degree
of liver impairment. Patients older than 50 years with a stage above the Milan criteria at transplantation have a poorer prognosis
after transplantation. Liver Transpl 14:526-533, 2008. © 2008 AASLD.
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Liver transplantation (LTX) is now accepted as a cura-
tive modality for early stage hepatocellular carcinoma
(HCC) on the basis of excellent 5-year survival rates
(71%-75%). These rates are comparable to those for
patients with advanced cirrhosis without malignan-
cies,1 Even outside the Milan criteria2 but within the
moderate expansion criteria of the University of Califor-
nia, San Francisco (UCSF), patients with HCC have an
acceptable 5-year period of survival.3
Nevertheless, the results of LTX for HCC in the liter-
ature are still discrepant. They derive from series in-
cluding a heterogeneous mixture of individuals in
terms of liver function, tumor stage, and deﬁnition of
outcomes (such as dropout for progressive malignancy,
recurrence of malignancy, and assessment of survival
on an intention-to-treat basis versus posttransplanta-
tion). The use of pre-LTX adjuvant therapy such as liver
resection, chemoembolization, or radiofrequency abla-
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tion (either as a downstaging procedure or to control the
evolution of the tumor while on the waiting list), may
also constitute an important confounding variable.
Studies are often small and single-center, and above
all, liver allocation policies for HCC vary greatly from
one allocation organization to another. The shortage of
organs, combined with the increased incidence of HCC
in the United States and Europe, largely due to the
medical consequences of the hepatitis C epidemic,
make it more crucial than ever to optimize the criteria of
both selection and priority for transplantation. Various
strategies have been adopted by the transplant commu-
nity, ranging from no priority for HCC (such as in the
current Eurotransplant system), to a center-oriented
system by which the local team chooses the recipient
who could beneﬁt most from the donor organ (a proce-
dure used in most other European centers) or to the
new allocation policy based on the Model for End-Stage
Liver Disease (MELD) adopted in the United States
since February 2002.4 The latter system, based on the
estimated risk of tumor progression within the Milan
criteria, has been shown to reduce the dropout rate and
increase the transplantation rate, while maintaining an
excellent post-LTX outcome.4,5 However, all these dif-
ferent sets of selection and priority criteria introduce
biases that inﬂuence the outcome of patients with HCC.
We therefore set out to identify, in a large multicenter
study, the predictive factors of the various outcomes for
HCC patients on the waiting list, with the aim of offering
the possibility of LTX to as many of those most likely to
be cured as possible. The fact that the Eurotransplant
allocation system used is patient-driven, but outside
the MELD system, gave us the unique opportunity to
estimate their natural history while on the waiting list.
PATIENTS AND METHODS
Between October 1, 1999 and October 1, 2004, 272
HCC patients belonging to the 6 Belgian transplant
centers, grouped into the Belgian Liver Intestine Com-
mittee of the Belgian Transplant Society, were consec-
utively listed for cadaveric LTX within the framework of
Eurotransplant, a foundation responsible for the allo-
cation of donor organs in Austria, Belgium, Germany,
Luxembourg, the Netherlands, and Slovenia. During
the same period, 955 patients with chronic liver disease
without malignancy were listed, so that our HCC pop-
ulation constituted 29% of the total Belgian series of
patients listed. The charts of these patients were retro-
spectively reviewed. During the study period, no listing
priority based on HCC characteristics alone was possi-
ble. According to the Eurotransplant allocation rules,
as from July 2000, only cirrhotic patients with a Child-
Turcotte-Pugh (CTP) score 10 and complications were
given priority and, from September 2003 the cutoff
point for this score was raised to 11.6
Only patients with a diagnosis of HCC at listing were
included in the present series. Their diagnosis was
based on parameters similar to those proposed by the
European Association for the Study of Liver diseases7:
either histological proof, or the presence of a nodule
with a diameter exceeding 2 cm, identiﬁed by ultra-
sonography and conﬁrmed to be hypervascular, either
at computed tomography (CT) or magnetic resonance
imaging or by 1 imaging study combined with an 
fetoprotein (FP) level above 400 ng/mL. HCC was con-
sidered as the primary diagnosis (n  226) when the
cancer was the reason for transplantation, and the sec-
ondary diagnosis (n  46) when decompensated cirrho-
sis was the indication, HCC being detected incidentally
during the prelisting workup.
Our study focused on the ﬁrst group, because it is the
most prevalent (226/272, 83%), for more homogeneous
results interpretation and to study the natural history
of the malignancy without the direct bias of the degree
of liver impairment. Patients with HCC were selected for
transplantation according to the Milan criteria2 as re-
quested by Eurotransplant and this was accepted by
the 6 transplant centers represented by the Belgian
Liver Intestine Committee, a national organization, rec-
ognized by Eurotransplant. Patients with extrahepatic
spread, assessed by bone scan and chest CT and/or
vascular invasion were excluded. During the waiting
period for LTX, imaging was repeated every 3 to 6
months. Delisting for tumor progression was decided
upon detection of either major vascular involvement or
extrahepatic spread.
Adjuvant therapy before listing or while waiting was
given to 123 of the 226 patients (54%), and consisted of
transarterial chemoembolization in 93 (76%), percuta-
neous alcoholization in 16 (13%), liver resection in 9
(7%), and radiofrequency ablation in 5 (4%).
Because of the absence of clear guidelines, the mag-
nitude of incorrect assessment of HCC staging by the
current imaging methods, and the availability of poten-
tially useful treatments, which either downstage the
tumor or limit its progression,8 these were decided
upon a case-by-case basis during the weekly multidis-
ciplinary medicosurgical conference in each center. In
particular, they were implemented in patients outside
the Milan criteria and/or in those who had tumor pro-
gression. This category of patients was also listed for a
marginal graft.
After listing for HCC, various distinct clinical out-
comes were considered. Before LTX, these comprised
the total number of failures (that is, death before delist-
ing and/or delisting because of tumor progression) and,
after LTX, overall mortality and HCC recurrence, while
the patients still alive were evaluated at the last fol-
low-up (April 1, 2005).
Thirteen categorical or continuous variables con-
cerning the prognostic value of all these outcomes
were analyzed. The clinical and demographic vari-
ables considered were age at listing and at transplan-
tation, gender, transplant center, waiting time, blood
group, year of listing, year of LTX, CTP score,9 and
MELD score.10
Tumor-related variables were FP at baseline, use of
prereferral or postreferral adjuvant therapy or no ther-
apy, the number of nodules, the size of the largest
nodule, the presence or absence of vascular invasion,
and tumor-node-metastasis (TNM) staging according to
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the American Liver Tumor Study group modiﬁcation
adopted by the United Network for Organ Sharing
(UNOS)11 and recently modiﬁed further by Yao et al.12
Tumor staging was based on preoperative imaging
UNOS clinical tumor-node-metastasis (cTNM) staging
and was evaluated at the time of listing and, after LTX,
from explant pathology using UNOS pathological tu-
mor-node-metastasis (pTNM) staging and American
Joint Committee on Cancer (AJCC)/International
Union Against Cancer (Union Internationale contre le
Cancer, UICC) criteria.13 Explanted liver was examined
by experienced local pathologists using 1-cm-thick sec-
tions. One of the 179 explanted liver specimens could
not be staged. The number of nodules, maximal tumor
size, and evidence of macrovascular involvement al-
lowed the evaluation of UNOS cTNM and pTNM, and the
differences between them.
The UNOS cTNM and pTNM staging used for our
study comprised the following: no HCC: absence of HCC
on the pathological specimen; T0: evidence of tumoral
necrosis within the explant, the disappearance of hy-
pervascularity on follow-up imaging after adjuvant
therapy, or tumor resection before transplantation; T1:
single nodule 2.0 cm; T2: single nodule 2-5 cm or 2 or
3 nodules 3 cm (that is, Milan criteria); T3: single
nodule 5 cm or 2 or 3 nodules, at least one 3.0 cm;
T3A: single nodule 6.5 cm or 3 nodules with the
largest lesion 4.5 cm and total tumor diameter 8 cm
(that is, UCSF criteria); T3B: T3 other than T3A; T4A: 4
or more nodules of any size; and T4B: T2, T3, or T4A
plus macroscopic intrahepatic portal or hepatic vein
involvement. The deﬁnition of the AJCC/UICC pTNM
was the following: T0, no evidence of tumor; T1, solitary
tumor without vascular invasion; T2, solitary tumor
with vascular invasion or multiple tumors, none more
than 5 cm; T3, multiple tumors more than 5 cm or
tumor involving a major branch of the portal or hepatic
vein(s); and T4, tumor(s) with direct invasion of adja-
cent organs other than the gallbladder or with perfora-
tion of visceral peritoneum. Tumor grading according to
the Edmonson criteria14 was available in 154 of the 178
pathological reports.
The liver transplant procedure involved only cadav-
eric donors.
Immunosuppressive therapy after LTX consisted of a
double or triple drug regimen of tacrolimus combined
with steroids and/or mycophenolate mofetil in the case
of renal failure. Tacrolimus was switched to cyclospor-
ine in the case of unstable diabetes or neurologic side
effects. Steroids were tapered gradually and discontin-
ued within 3 months.
All patients were followed regularly at the outpatient
clinic. The frequency of visits varied according to the
patient’s condition and type of complications.
Screening for HCC recurrence after LTX was done by
ultrasound and FP measurement every 6 months, ab-
dominal CT every year, with bone scan, magnetic reso-
nance imaging, or chest CT if necessary. No adjuvant
chemotherapy was administered.
Statistical Analysis
Univariate and multivariate analyses of the potential
prognostic variables were performed for the various
outcomes, that is, risk of death and dropout on the
waiting list before LTX, death, and recurrence of HCC
after LTX.
In each analysis, failures due to events other than the
event of interest were treated as censored observations.
In the univariate analysis, categorical variables were
compared using the chi-square or Fisher’s exact tests,
as appropriate. Continuous variables were compared
using the nonparametric Mann-Whitney test or the
Student t test (if they were Gaussian), or logarithmically
transformed for the skewed variables. They were cate-
gorized in two groups, the cutoff value being selected in
a pragmatic way in order to obtain the highest possible
statistical signiﬁcant difference between the survival
curves. To assess the risk factors for the different out-
comes, Cox hazard regression models were constructed
and the relative risks estimated, together with their
95% conﬁdence intervals.
Only variables which emerged with a P value 0.1
after univariate analysis were included in the Cox mod-
el.15 They were selected stepwise for statistical signiﬁ-
cance. The proportional assumption of the Cox model
was graphically veriﬁed by the linear relationship be-
tween the logn (ln) of cumulative events and the ln of
time.16 Graphic displays of the results were obtained
using the actuarial method and the survival curves for
a given prognostic factor were adjusted using stratiﬁ-
cation in order to account for the inﬂuence of the other
factors, thus avoiding confounding biases. Calculations
were carried out using the StatView program.17
RESULTS
Baseline Demographic Data Including Patient
and Tumor Characteristics
The general characteristics of the 226 patients with
primary HCC are given in Table 1.
Most patients were men (79%), and 42% had hepatitis
C virus as the underlying liver disease. Median CTP and
MELD scores at listing were 6.7 and 9.3, respectively.
The number of patients listed yearly was fairly con-
stant, taking into account the fact that in 1999 and
2004, the inclusion periods considered were 3 and 9
months, respectively.
At listing, 149 patients (66%) were candidates for LTX
according to the Milan criteria (that is, T1 or T2), 29
(13%) were within the UCSF criteria and 48 (21%) did
not fulﬁll the UCSF or Milan criteria and were listed for
a marginal graft for which no other recipient was avail-
able for that organ.
Survival According to Intention-to-Treat and
Post-LTX
The 6-month and 1-, 2-, 3-, and 4-year survival rates for
the 226 patients listed with primary HCC, according to
intention-to-treat analysis (time zero point being the
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inclusion of the subject on the waiting list) were 84, 74,
63, 58, and 56%, respectively. For those actually receiv-
ing transplantation, the corresponding survival rates
were 84, 79, 72, 69, and 66%, respectively (Fig. 1). The
10% difference between the 2 curves reﬂected failure of
the listing due to dropout, or death before dropout.
Probability of Pre- and Post-LTX Outcomes
and Prognostic Factors
The actuarial probabilities of the most pertinent pre-
LTX events in the 226 patients listed with primary HCC,
that is, failures to get a transplant and chance of re-
ceiving a graft, show a 24% and 78% rate at 18 months,
respectively (Fig. 2). The results of stepwise Cox regres-
sion analysis of the impact of the 13 baseline variables
on these outcomes are given in Table 2, with their cutoff
values, regression coefﬁcient, standard error, statisti-
cal signiﬁcance, relative risk, and 95% conﬁdence in-
tervals.
Of the 226 patients listed, 30 were delisted (19 for
tumor progression, 2 for severe liver failure, 1 for social
reasons, 5 for noncompliance, and 3 for responding
well to adjuvant therapy). Ten patients died before be-
ing delisting (3 of sepsis, 2 of liver failure, 2 of cardio-
vascular events, 1 of tumor progression, 1 of cytomeg-
alovirus hepatitis, and 1 of unknown reason). Twenty-
nine (12.8%) patients, including the 19 delisted for
tumor progression and the 10 who died before delisting,
were thus considered as pre-LTX failures.
Based on the multivariate analysis, CTP score 9,
(relative risk [RR] 4.1), FP  100 ng/mL at baseline
(RR 3.0), and preoperative adjuvant therapy (RR 2.5)
were independent risk factors for a failure to get a
transplant in time (Table 2). One hundred forty-ﬁve of
the 226 (64%) patients were transplanted after a me-
dian waiting period of 4 months (range, 0-27.2). The
waiting time (mean  standard error of the mean) in-
creased steadily with the year of listing: 1999, 2.6 
Figure 1. Patient survival after liver transplantation
(TRANSPLANT) and according to intention to treat (ITT).
TABLE 1. Baseline Characteristics of the 226 Patients with Primary HCC Listed for Transplantation
Median age, years (range) 58 (17–72)
Gender: male/female (%) 173 (77)/57 (23)
ABO blood group n: O/A/B/AB 78/111/28/9
Transplant center: KUL/GUH/UHA/UCL/ULB/ULg 92/32/9/46/24/23
Etiology of underlying liver disease n (%): HCV/alcohol/other 96 (42)/65 (29)/65 (29)
Listing per year n: 1999/2000/2001/2002/2003/2004 8/42/30/46/64/36
UNOS TNM staging at listing n (%): T1/T2/T3A/T3B/T4A 20 (9)/129 (57)/29 (13)/11 (5)/37 (16)
Adjuvant therapy n  123 (54%) n (%): TACE/alcoholization/resection/RF 93 (76)/16 (13)/9 (7)/5 (4)
Median Child-Turcotte-Pugh score (range) 6.7 (5–13)
Median MELD score (range) 9.3 (6–30)
Abbreviations: GUH, Ghent University Hospital; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C
virus; KUL, Katholieke Universiteit Leuven; MELD, Model for End-Stage Liver Disease; RF, radiofrequency ablation; TACE,
transarterial chemoembolisation; TNM, tumour node metastasis; UCL, Universite´ Catholique de Louvain; ULB, Universite´
Libre de Bruxelles; ULg, Universite´ de Lie`ge; UZA, Universiy Hospital Antwerpen.
Figure 2. Cumulative probability (%) of transplantation and
dropout after inclusion on the waiting list for patients on the
waiting list with primary HCC.
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0.7; 2000, 4.2.  0.9; 2001, 6.8  1.1; 2002, 7.1  0.8;
and 2003-2004, 3.7  1.7 months.
Probabilities of Post-LTX Outcomes and
Prognostic Factors
The actuarial post-LTX risks of overall mortality and
probability to remain free of HCC recurrence for the 145
patients actually transplanted are illustrated in Fig. 3,
showing a rate of death and recurrence of 34% and 17%
at 4 years. Patient survival after LTX is thus 66% at 4
years. HCC recurred in 14 patients (10%), after a mean
period 11 3.8 months (range, 2-46). Two independent
risk factors predicted HCC recurrence: FP 100 ng/m
and presence of vascular invasion on the hepatectomy
specimen, with RRs of 3.2 and 3.6, respectively (Table
2). Forty-ﬁve patients died after LTX, because of sepsis
in 13, recurrent HCC in 15, cardiovascular problems in
3, perioperative problems in 2, HCV recurrence in 2,
gastrointestinal hemorrhage in 1, liver failure in 1, de
novo neoplasms in 5, and unknown reasons in 3. Only
UNOS pTNM above T2 (RR 2.1) and age above 50 years
(RR 2.5) were signiﬁcant predictors of post-LTX death.
When the AJCC/UICC TNM was included in the Cox
multivariate regression analysis, it did not add signiﬁ-
cant independent discriminative power (P  0.48).
Correlation Between Clinical and Pathological
TNM
The ﬁndings by pre-LTX imaging at the time of listing
were different from the pathological ﬁndings in a signif-
icant number of patients, based on the 144 hepatec-
tomy specimens (data not shown). The mean and me-
dian periods between UNOS cTNM at listing and UNOS
pTNMwere 5.4 and 4.4 months, respectively. No tumor,
T0 stage, same staging, understaging (more lesions in
the explanted liver, that is, UNOS pTNM, than those
observed by preoperative imaging, that is, UNOS
cTNM), and overstaging (more lesions on UNOS cTNM
than UNOS pTNM) were observed in 8.3% (12/144),
11.1% (16/144), 34% (49/144), 10.4% (15/144), and
36.2% (52/144), respectively.
DISCUSSION
In this large multicenter series of HCC patients from a
European region where only patients with decompen-
sated cirrhosis receive priority for LTX, we have identi-
ﬁed a subset of patients at high risk of not receiving
transplantation either because of death before delisting
or dropout because of tumor progression. Their identi-
ﬁcation is based on tumor characteristics and the de-
gree of liver impairment caused by the underlying liver
disease.
The importance of an intention-to-treat analysis to
evaluate the beneﬁt of LTX as a treatment of HCC was
ﬁrst suggested by Llovet et al.18 and was subsequently
emphasized by other groups.19,20 On the basis of our
intention-to-treat analysis, we obtained a 10% differ-
ence in comparison with the 66% 4-year actuarial sur-
vival, which reﬂected the natural history of our HCC
patients on the waiting list, for whom there was no












Child-Turcotte-Pugh score 9–13 1.411 0.447 0.002 4.1 (1.7–9.9)
FP (ng/mL) 100 1.089 0.442 0.014 3.0 (1.2–7.1)
Preoperative therapy Yes 0.924 0.442 0.037 2.5 (1.1–6.0)
Recurrence of HCC after
LTX (n  14)
FP (ng/mL) 100 1.178 0.572 0.039 3.2 (1.1–10.0)
Vascular involvement Yes 1.278 0.587 0.029 3.6 (1.1–11.3)
Deaths after LTX
(n  45)
Patient age (years) 50 0.911 0.444 0.040 2.5 (1.0–5.9)
UNOS pTNM 2 0.680 0.326 0.037 2.1 (1.0–3.7)
Abbreviation: CI, conﬁdence interval.
Figure 3. Actuarial cumulative rate of mortality and HCC
recurrence after transplantation.
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priority bias. For the patients actually receiving trans-
plantation, our 6-month, 1-, 2-, 3-, and 4-year long-
term survival rates were 84, 79, 72, 69, and 66%, re-
spectively, together with a low (10%) actuarial incidence
of recurrent HCC, results which are comparable to
those recently reported.21 Our results conﬁrm that FP
is an important predictor of poor pre-LTX clinical out-
come22,23 and suggests that this simple, objective bio-
logical parameter could be used to reﬁne the transplant
allocation policy for HCC patients listed for LTX. Apart
from FP, we showed that the degree of liver impair-
ment, a determining element for the organ allocation
decisions, still represents a signiﬁcant risk factor for
failure to get a transplant in due time. This is a striking
observation that has already been noted by an Italian24
and a Chinese25 group, outside the MELD priority pol-
icy, reporting that the dropout rate before transplanta-
tion was related to CTP score, regardless of the preop-
erative diagnosis of HCC. Our analysis indicates that
the best cutoff point for deﬁning risk of liver failure, in
the presence of primary HCC, is a CTP score of 9 or
more. This underlines the fact that the critical thresh-
old may be lower for HCC than for patients with cirrho-
sis without HCC, for whom the CTP has been estimated
at 11.26 It must be emphasized that for our patients
listed for HCC and not for end-stage liver disease, the
MELD score was not a predictive factor of LTX failure,
when competing with the CTP score in the multivariate
analysis. Moreover, it was not statistically signiﬁcant
(P  0.67; data not shown) in the univariate analysis.
The reasons for this observation are probably related to
the high power of serum creatinine in the MELD score, a
parameter not directly measuring liver failure in its early
stage; this conﬁrms recent data showing thatMELD score
is an excellent predictor of short-term mortality on the
waiting list27 only when this score is high, reﬂecting ad-
vanced liver disease associated with renal failure.
Our data demonstrate that the true stage of HCC was
underestimated in 10.4% of our patients, the values
reported in the literature being 20 to 30%.20 Absence of
HCC on the hepatectomy specimen was seen in 8.3%,
this being observed in 10 to 31% for UNOS TNM stage 1
lesions in the literature.4,28 Overstaging was observed
in a high percentage of cases (36%), thus conﬁrming
that the diagnostic accuracy and adequate character-
ization of nodules in patients with cirrhosis is low with
the currently used imaging techniques.29,30 This sug-
gests performing more biopsies of sizable nodules in
cirrhosis,31 but the lack of sensitivity, potential risks,
and difﬁcult access to the lesion, as well as the risk of
seeding, are major objections.
In our study, adjuvant therapy, comprising mostly
chemoembolization, was more detrimental than bene-
ﬁcial in increasing the chance of being transplanted.
Possible reasons for the absence of a positive effect of
adjuvant therapies might be potential selection biases,
due to its use in more advanced disease and the harm-
ful effects of such therapies.32-35 Thus, at the present
time, the role of adjuvant therapy remains to be proven
and trials comparing treatment versus no treatment for
patients on the waiting list are needed.8 As the overall
waiting period was short for our series, it was not a
signiﬁcant prognostic factor of post-LTX events. When
the waiting period exceeded 12months, we observed, as
seen in Fig. 2, that the failure rate increased above 20%,
thus conﬁrming other reports.36
The most powerful and signiﬁcant predictor of death
after LTX was patient age and a high risk (greater than
T2) UNOS pTNM stage, in agreement with previous re-
ports.37-40 The negative impact of older age on patient
survival has been emphasized in large series but they
did not include an HCC population.41 If our data are
conﬁrmed by others, this will suggest that, unless mar-
ginal donors are considered, expanding the criteria
above the Milan criteria will only be justiﬁed for pa-
tients less than 50 years old, in order to keep the 5-year
survival above the cutoff point of 50%.42 Our study
showed that the pTNM classiﬁcation proposed by the
UICC and the AJCC did not add signiﬁcant independent
prognostic value compared to the UNOS pTNM for eval-
uating post-LTX survival. Besides this, the interest in
the latter is that it can be evaluated both on explant
pathology and on preoperative imaging and it incorpo-
rates the Milan (UNOS T2) as well as the UCSF (UNOS
T3A) staging criteria, which are now well accepted and
largely applied as an estimation of tumor burden.2,3
Only HCC patients meeting UNOS T2 criteria by imag-
ing are currently eligible for receiving priority listing for
LTX under the MELD model in the United States and,
since January 1, 2007, also in the Eurotransplant
group.
In comparison with other series in which HCC recur-
rence after LTX varies from 10 to 50%,43,44 our 10%
rate is low, even though 34% of the patients were listed
outside the Milan criteria and 21% outside Yao’s crite-
ria. Only vascular invasion or its surrogate marker, FP
was able to alter the prognosis by causing recurrence,
in a minority of patients. This is an argument favoring
the concept of modest expansion of the Milan criteria.
Another reason could be in relation with the poor stag-
ing capability of preoperative imaging, demonstrated by
this series and others.
In conclusion, both tumor characteristics and the
degree of liver impairment, with a CTP equal or higher
than 9, should be taken into consideration when offer-
ing priority on the waiting list for patients with cirrhosis
with HCC.
Older patients with an HCC above the Milan criteria
based on explant pathology have a poorer prognosis
after transplantation. However, this category of pa-
tients is difﬁcult to identify at listing because of the poor
correlation between preoperative imaging and explant
pathological stage. Our data may help in making policy
decisions regarding liver allocation for patients with
HCC, in particular in the European regions, where
there is currently no priority for HCC patients on the
waiting list.
ACKNOWLEDGMENT
We thank F. Roggen, L. Colenbie, P. Finet, E. De Gendt,
and G. Bonduel for their invaluable help in collecting
LIVER TRANSPLANTATION FOR HCC WITHIN EUROTRANSPLANT 531
LIVER TRANSPLANTATION.DOI 10.1002/lt. Published on behalf of the American Association for the Study of Liver Diseases
the data, and Drs. R. Aerts, J.B. de Hemptinne, J. de
Ville de Goyet, M. Gelin, P. Honore´, and D. Ysebaert for
allowing us to review their data.
REFERENCES
1. Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplan-
tation for hepatocellular carcinoma. Gastroenterology
2005;128:1752-1764.
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A,
Bozzetti F, et al. Liver transplantation for the treatment of
small hepatocellular carcinomas in patients with cirrho-
sis. N Engl J Med 1996;334:693-699.
3. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL,
Roberts JP. Liver transplantation for hepatocellular car-
cinoma: comparison of the proposed UCSF criteria with
the Milan criteria and the Pittsburgh modiﬁed TNM cri-
teria. Liver Transpl 2002;8:765-774.
4. Wiesner RH, Freeman RB, Mulligan DC. Liver transplan-
tation for hepatocellular cancer: the impact of the MELD
allocation policy. Gastroenterology 2004;127:S261–S267.
5. Sharma P, Balan V, Hernandez JL, Harper AM, Edwards
EB, Rodriguez-Luna H, et al. Liver transplantation for hep-
atocellular carcinoma: the MELD impact. Liver Transpl
2004;10:36-41.
6. Eurotransplant Newsletter 2003;189:5.
7. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R,
Burroughs AK, et al. Clinical management of hepatocellu-
lar carcinoma. Conclusions of the Barcelona-2000 EASL
conference. European Association for the Study of the
Liver. J Hepatol 2001;35:421-430.
8. Majno P, Giostra E, Morel P, Hadengue A, Mentha G;
Geneva Liver Cancer Study Group. Management of hepa-
tocellular carcinoma in the waiting list before liver trans-
plantation. J Hepatol 2005;42:S134–S143.
9. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC,
Williams R. Transection of the oesophagus for bleeding
oesophageal varices. Br J Surg 1973;60:646-649.
10. Wiesner R, Edwards E, Freeman R, Harper A, Kim R,
Kamath P, et al. Model for End-Stage Liver Disease
(MELD) and allocation of donor livers. Gastroenterology
2003;124:91-96.
11. United Network for Organ Sharing. Available at: http://
www.unos.org. Accessed December 5, 2007.
12. Yao FY, Bass NM, Ascher NL, Roberts JP. Liver trans-
plantation for hepatocellular carcinoma: lessons from
the ﬁrst year under the Model of End-Stage Liver Dis-
ease (MELD) organ allocation policy. Liver Transpl
2004;10:621-630.
13. Liver (including intrahepatic bile ducts). In: Green FL,
Page DL, Fleming ID, American Joint Committee on Can-
cer, American Cancer Society, eds. AJCC Cancer Staging
Manual. 6th ed. New York: Springer-Verlag; 2002:131-
144.
14. Edmonson HA, Steiner PE. Primary carcinoma of the liver:
a study of 100 cases among 48.900 necropsies. Cancer
1954;7:462-503.
15. Cox DR, Oakes D. Analysis of survival data. London:
Chapman and Hall; 1984.
16. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A com-
parison of goodness-of-ﬁt tests for the logistic regression
model. Stat Med 1997;16:965-980.
17. Abacus concepts. Survival tools for Stat View. Berkeley,
CA: Abaccus Concepts; 1994.
18. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of
surgical treatment for early hepatocellular carcinoma: re-
section versus transplantation. Hepatology 1999;30:
1434-1440.
19. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wut V,
et al. Liver transplantation for hepatocellular carcinoma:
analysis of survival according to the intention-to-treat
principle and dropout from the waiting list. Liver Transpl
2002;8:873-883.
20. Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen
CB, Kremers WK, Gores G. Drop-out rates of patients with
hepatocellular cancer listed for liver transplantation: out-
come with chemoembolization. Liver Transpl 2004;10:449-
455.
21. Roayaie S, Llovet JM. Liver transplantation for hepatocel-
lular carcinoma: is expansion of criteria justiﬁed? Clin
Liver Dis 2005;9:315-328.
22. Yamashiki N, Gaynor JJ, Kato T, Reddy KR, Sobhonslid-
suk A, Levi D, et al. Competing risks analysis of predictors
of delisting owing to tumour progression in liver trans-
plant candidates with hepatocellular carcinoma. Am J
Transplant 2004;4:774-781.
23. Fisher RA, Maluf D, Cotterell AH, Stravitz T, Wolfe L,
Luketic V, et al. Non-resective ablation therapy for hepa-
tocellular carcinoma: effectiveness measured by inten-
tion-to-treat and dropout from liver transplant waiting
list. Clin Transplant 2004;18:502-512.
24. Ravaioli M, Grazi GL, Ballardini G, Cavrini G, Ercolani G,
Cescon M, et al. Liver transplantation with the MELD
system: a prospective study from a single European cen-
ter. Am J Transplant 2006;6:1572-1577.
25. Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Hunag YH, et al.
Determination of the optimal Model for End-Stage Liver
Disease score in patients with small hepatocellular carci-
noma undergoing loco-regional therapy. Liver Transpl
2004;10:1507-1513.
26. Degre D, Bourgeois N, Boon N, Le Moine O, Louis H,
Donckier V, et al. Aminopyrine breath test compared to
the MELD and Child-Pugh scores for predicting mortality
among cirrhotic patients awaiting liver transplantation.
Transpl Int 2004;17:31-38.
27. Everson GT. MELD: the answer or just more questions?
Gastroenterology 2003;124:251-254.
28. Olthoff KM, Brown RS Jr, Delmonico FL, Freeman RB,
McDiarmid SV, Merion RM, et al. Summary report of a
national conference: evolving concepts in liver allocation
in the MELD and PELD era. December 8, 2003, Washing-
ton, DC, USA. Liver Transpl 2004;10:A6–A22.
29. Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D,
Pirenne J, Nevens F, et al. Focal lesions in cirrhotic ex-
plant livers: pathological evaluation and accuracy of pre-
transplantation imaging examinations. Liver Transpl
2002;8:749-761.
30. Freeman RB, Mithoefer A, Ruthazer R, Nguyen K, Schore
A, Harper A, Edwards E. Optimizing staging for hepatocel-
lular carcinoma before liver transplantation: a retrospec-
tive analysis of the UNOS/OPTN database. Liver Transpl
2006;12:1504-1511.
31. Caturelli E, Solmi L, Anti M, Fusilli S, Roselli P, Andriulli
A, et al. Ultrasound guided ﬁne needle biopsy of early
hepatocellular carcinoma complicating liver cirrhosis: a
multicentre study. Gut 2004;53:1356-1362.
32. Bruix J, Sala M, Llovet JM. Chemoembolization for hepa-
tocellular carcinoma Gastroenterology 2004;127:S179–
S188.
33. Otto G, Herber S, Heise M, Lohse AW, Monch C, Bittinger
F, et al. Response to transarterial chemoembolization as a
biological selection criterion for liver transplantation in
hepatocellular carcinoma. Liver Transpl 2006;12:1260-
1267.
34. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G,
Hashizume K, et al. Liver resection as a bridge to trans-
plantation for hepatocellular carcinoma on cirrhosis: a
reasonable strategy? Ann Surg 2003;238:508-518.
35. Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix
532 ADLER ET AL.
LIVER TRANSPLANTATION.DOI 10.1002/lt. Published on behalf of the American Association for the Study of Liver Diseases
L, et al. Increased risk of tumour seeding after percutane-
ous radiofrequency ablation for single hepatocellular car-
cinoma. Hepatology 2001;33:1124-1129.
36. Bruix J, Llovet JM. Prognostic prediction and treatment
strategies in hepatocellular carcinoma. Hepatology 2002;
35:519-524.
37. Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S,
Sun W, et al. Liver transplantation for hepatocellular car-
cinoma validation of present selection criteria in predict-
ing outcome. Liver Transpl 2004;10:911-918.
38. Herrero JI, Sangro B, Quiroga J, Pardo F, Herraiz M,
Cienfuegos JA, Prieto J. Inﬂuence of tumour characteris-
tics on the outcome of liver transplantation among pa-
tients with liver cirrhosis and hepatocellular carcinoma.
Liver Transpl 2001;7:631-636.
39. Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A,
Garrigan K, et al. Liver transplantation outcomes for
early-stage hepatocellular carcinoma: results of a multi-
center study. Liver Transpl 2004;10:1343-1354.
40. Vauthey JN, Ribero D, Abdalla EK, Jonas S, Bharat A,
Schumacher G, et al. Outcomes of liver transplantation in
490 patients with hepatocellular carcinoma: validation of
a uniform staging after surgical treatment. J Am Coll Surg
2007;204:1016-1027.
41. Busuttil RW, Farmer DG, Yersiz H, Hiatt JR, McDiarmid
SV, Goldstein LI, et al. Analysis of long-term outcomes of
3200 liver transplantations over two decades: a single-
center experience. Ann Surg 2005;241:905-916.
42. Bruix J, Llovet JM. Prognostic prediction in HCC: did
anyone expected to be easy? Hepatology 2004;39:551-
552.
43. Marsh JW, Casavilla A, Iwatsuki S, Dvorchik I, Subotin M,
Balan V, et al. Predicting the risk of tumor recurrence
following transplantation for hepatocellular carcinoma.
Hepatology 1997;26:1689-1691.
44. Vivarelli M, Cucchetti A, Piscaglia F, La Barba G, Bolondi
L, Cavallari A, Pinna AD. Analysis of risk factors for tumor
recurrence after liver transplantation for hepatocellular
carcinoma: key role of immunosuppression. Liver Transpl
2005;11:497-503.
LIVER TRANSPLANTATION FOR HCC WITHIN EUROTRANSPLANT 533
LIVER TRANSPLANTATION.DOI 10.1002/lt. Published on behalf of the American Association for the Study of Liver Diseases
